Novel fenoterol derivatives as suppressors of ERK1/2 phosphorylation in melanoma
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026
DOI: 10.1007/s00210-026-05564-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Jakub Wójcik und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biopharmacy, Medical University of Lublin, Lublin, Poland. Hauptthemen laut MEDLINE: Fenoterol, Melanoma, Antineoplastic Agents, Mitogen-Activated Protein Kinase 1. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Melanoma is a highly aggressive cancer with limited therapeutic options. In melanoma cell lines, β 2 AR activation leads to the suppression of pro-proliferatory MAPK/ERK signaling. This suggests that fenoterol, a potent β 2 AR agonist, can be useful in the treatment of melanoma. Here, we investigated the structure–activity relationship (SAR) of fenoterol derivatives for β 2 AR-depedent ERK suppression. We used the UACC-647 human-derived melanoma cell line to screen a panel of chiral compounds based on the fenoterol scaffold. The levels of phosphoactive ERK1/2 were quantified by immunoblotting. Anti-tumorigenic activity of the drugs was assessed using MTS assay and zebrafish xenograft model. ( R , R ′) stereoisomers of fenoterol derivatives exhibited the highest suppression of ERK phosphorylation, followed by ( R , S ′) and ( S , R ′) isomers, with ( S , S ′) isomers being the least active, mirroring trends observed in β 2 AR binding and cAMP accumulation. SAR analysis revealed that modifications to the α′ alkyl chain and the 4′-hydroxy moieties significantly affected ERK-inhibitory activity of fenoterol derivatives. ( R , R ′)-4′-hydroxy-1-naphthylfenoterol [( R , R ′)-HNF] was the most active inhibitor of ERK activation with an IC 50 of 0.03 nM. However, it showed minimal anti-proliferative activity in the zebrafish xenograft model. In contrast, ( R , R ′)-4′-methoxy-1-naphthylfenoterol [( R , R ′)-MNF], a weaker ERK inhibitor (IC 50 = 0.17 nM), significantly reduced cell viability in vitro (IC 50 = 14.07 µM) and tumor growth in vivo. SAR for fenoterol-mediated ERK inhibition in melanoma was defined, highlighting the importance of the ( R , R ′) stereochemistry. Crucially, potent ERK inhibition does not directly predict anti-tumorigenic activity, as shown by ( R , R ′)-HNF. The pronounced anti-proliferatory effect of ( R , R ′)-MNF, despite weaker ERK inhibition, implies additional mechanisms beyond ERK modulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biopharmacy, Medical University of Lublin, Lublin, Poland.
- Doctoral Schoolof the Medical University of Lublin, Lublin, Poland.
- Department of Medical Chemistry, Medical University of Lublin, Lublin, Poland.
- Laboratory of Clinical Investigation, National Institute on Aging, National Institutes of Health, Baltimore, MD, USA.
- PAZ Pharma, Mullica Hill, Harrison, NJ, USA.
- Department of Biopharmacy, Medical University of Lublin, Lublin, Poland. artur.wnorowski@umlub.edu.pl.
Zitieren
APA
Wójcik, J., Wnorowska, S., Miziewicz, W., Tassinari, G., Misiurek, G., Kostecki, R., Małek, A., Boguszewska-Czubara, A., Wainer, I. W., & Wnorowski, A. (2026). Novel fenoterol derivatives as suppressors of ERK1/2 phosphorylation in melanoma. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-026-05564-7
Vancouver
Wójcik J, Wnorowska S, Miziewicz W, Tassinari G, Misiurek G, Kostecki R, et al. Novel fenoterol derivatives as suppressors of ERK1/2 phosphorylation in melanoma. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-026-05564-7
BibTeX
@article{Wjcik2026,
author = {Wójcik, Jakub and Wnorowska, Sylwia and Miziewicz, Weronika and Tassinari, Giulia and Misiurek, Gabriela and Kostecki, Robert and Małek, Agata and Boguszewska-Czubara, Anna and Wainer, Irving W and Wnorowski, Artur},
title = {Novel fenoterol derivatives as suppressors of ERK1/2 phosphorylation in melanoma},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
doi = {10.1007/s00210-026-05564-7}
}
EUVIMED